Amidst reaching an acquisition deal that brings Ipsen a commercialized drug for follicular lymphoma, the Paris-based drugmaker is expanding its reach in cancer through license deal which took him into…
As a mother of two young boys, Ellen Da Silva said she and other parents in the US feel “in general, they feel quite underserved by the existing pediatric care…
Never before have clinical researchers had more choices in study design. As technology advances, companies send more notifications, collect larger amounts of data, and add more apps, wearables, and ePROs…
A precision medicine is only as good as its target. Although targeted therapies now target many types of cancer, tumors still often develop mutations that help them escape the drug.…
Cardiology has a heart attack, oncology has the fateful date of diagnosis, but there is no “kidney attack” to serve as a traumatic wake-up call for those at risk of…
Even before Covid-19 disrupted the traditional model for clinical trials, researchers were harnessing the power of technology to make trials more accessible and improve data collection. The movement has coalesced…
FDA approval of Arcutis Biotherapeutics’ new drug for plaque psoriasis allows the company to implement a strategy it believes will win both payers and patients — lower prices. Arcutis has…